{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:41:54Z","timestamp":1787013714151,"version":"build-2736575974"},"reference-count":49,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2019,10,23]],"date-time":"2019-10-23T00:00:00Z","timestamp":1571788800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Ther Apher Dial"],"published-print":{"date-parts":[[2020,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Patients with chronic kidney disease often develop secondary hyperparathyroidism (SHPT), marked by high levels of circulating parathyroid hormone (PTH) and increased risk of morbidity and mortality. Patients with SHPT are treated with a therapeutic combination that commonly includes calcimimetics, which have recently become popular in clinical settings, and other agents such as vitamin D preparations. Calcimimetics are a drug class that reduces PTH levels by targeting the calcium\u2010sensing receptor. Cinacalcet, a representative calcimimetic, is widely used; however, a high incidence of upper gastrointestinal (GI) tract\u2010related adverse events (AEs) can result in insufficient dosage and poor long\u2010term compliance. The newly approved evocalcet has equivalent efficacy to cinacalcet at a lower clinical dose, with improved bioavailability, fewer upper GI tract\u2010related AEs, and fewer safety concerns. This review gives an overview of calcimimetic agents, with a special focus on evocalcet, and describes the clinical advantages of evocalcet in the treatment of dialysis patients with SHPT.<\/jats:p>","DOI":"10.1111\/1744-9987.13434","type":"journal-article","created":{"date-parts":[[2019,9,5]],"date-time":"2019-09-05T03:25:05Z","timestamp":1567653905000},"page":"248-257","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Evocalcet: A New Oral Calcimimetic for Dialysis Patients With Secondary Hyperparathyroidism"],"prefix":"10.1111","volume":"24","author":[{"given":"Tadao","family":"Akizawa","sequence":"first","affiliation":[{"name":"Division of Nephrology, Department of Medicine Showa University School of Medicine  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6096-4723","authenticated-orcid":false,"given":"Kazuaki","family":"Ikejiri","sequence":"additional","affiliation":[{"name":"R&amp;D Division, Kyowa Kirin Co., Ltd.  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Kondo","sequence":"additional","affiliation":[{"name":"R&amp;D Division, Kyowa Kirin Co., Ltd.  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Endo","sequence":"additional","affiliation":[{"name":"R&amp;D Division, Kyowa Kirin Co., Ltd.  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Fukagawa","sequence":"additional","affiliation":[{"name":"Division of Nephrology Endocrinology and Metabolism, Tokai University School of Medicine  Kanagawa Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,10,23]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ki.5000414"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0158765"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/1744-9987.12772"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10157-011-0502-5"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.06040710"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2013.08.011"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/MNH.0000000000000326"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1590\/S0004-27302006000400008"},{"issue":"4","key":"e_1_2_5_10_1","first-page":"S1","article-title":"K\/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease","volume":"42","author":"National Kidney Foundation","year":"2003","journal-title":"Am J Kidney Dis"},{"issue":"113","key":"e_1_2_5_11_1","first-page":"S1","article-title":"KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease\u2010Mineral and Bone Disorder (CKD\u2010MBD)","volume":"76","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD\u2010MBD Work Group","year":"2009","journal-title":"Kidney Int Suppl"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/1744-9987.12058"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/1744-9987.12030"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2005.06.019"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.95.7.4040"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/1744-9987.12352"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2010.167"},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1205624"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfq725"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/srep19612"},{"key":"e_1_2_5_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2005.00596.x"},{"key":"e_1_2_5_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/sdi.12413"},{"key":"e_1_2_5_23_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.12941213"},{"key":"e_1_2_5_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfm534"},{"key":"e_1_2_5_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1542-4758.2009.00397.x"},{"key":"e_1_2_5_26_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI119413"},{"key":"e_1_2_5_27_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.1998.274.1.G122"},{"key":"e_1_2_5_28_1","first-page":"455","article-title":"The effects of cinacalcet on vagus nerve in miniature pigs","volume":"82","author":"Kondo Y","year":"2017","journal-title":"Kidney dial"},{"key":"e_1_2_5_29_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270007304103"},{"key":"e_1_2_5_30_1","first-page":"396","article-title":"Etelcalcetide (parsabiv) for secondary hyperparathyroidism in adults with chronic kidney disease on hemodialysis","volume":"43","author":"Patel J","year":"2018","journal-title":"P T"},{"key":"e_1_2_5_31_1","first-page":"1723","article-title":"A phase 3, muticentre, randomized, double\u2010blind, placebo\u2010controlled, parallel\u2010group study to evaluate the efficacy and safety of etelcalcetide (ONO\u20105163\/AMG 416), a novel intravenous calcimimetic, for secondary hyperparathyroidism in Japanese haemodialysis patients","volume":"32","author":"Fukagawa M","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"e_1_2_5_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2017.01.016"},{"key":"e_1_2_5_33_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.19468"},{"key":"e_1_2_5_34_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.19456"},{"key":"e_1_2_5_35_1","unstructured":"Kyowa Hakko Kirin receives approval for ORKEDIA\u00ae Tablets (Evocalcet) for the treatment of secondary hyperparathyroidism in patients on maintenance dialysis in Japan. [Accessed 23 Jan 2019.] Available from URL:https:\/\/www.kyowa-kirin.com\/news_releases\/2018\/pdf\/e20180323_01.pdf"},{"key":"e_1_2_5_36_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0195316"},{"key":"e_1_2_5_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2018.04.055"},{"key":"e_1_2_5_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10157-019-01692-y"},{"key":"e_1_2_5_39_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S134103"},{"key":"e_1_2_5_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-018-0687-4"},{"key":"e_1_2_5_41_1","first-page":"101","article-title":"Pharmacokinetics of evocalcet in secondary hyperparathyroidism patients receiving hemodialysis: first\u2010in\u2010patient clinical trial in Japan","volume":"10","author":"Shigematsu T","year":"2018","journal-title":"Clin Pharm"},{"key":"e_1_2_5_42_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10157-018-1635-6"},{"key":"e_1_2_5_43_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200565020-00007"},{"key":"e_1_2_5_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12588"},{"key":"e_1_2_5_45_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0204896"},{"key":"e_1_2_5_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2018.05.013"},{"key":"e_1_2_5_47_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-42017-z"},{"key":"e_1_2_5_48_1","doi-asserted-by":"publisher","DOI":"10.1254\/fpj.154.35"},{"key":"e_1_2_5_49_1","doi-asserted-by":"publisher","DOI":"10.1159\/000156717"},{"key":"e_1_2_5_50_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-018-0737-y"}],"container-title":["Therapeutic Apheresis and Dialysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1744-9987.13434","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/1744-9987.13434","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1744-9987.13434","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T07:21:22Z","timestamp":1693293682000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1744-9987.13434"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,23]]},"references-count":49,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["10.1111\/1744-9987.13434"],"URL":"https:\/\/doi.org\/10.1111\/1744-9987.13434","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.737475374.793577515","asserted-by":"object"}]},"ISSN":["1744-9979","1744-9987"],"issn-type":[{"value":"1744-9979","type":"print"},{"value":"1744-9987","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,23]]},"assertion":[{"value":"2019-05-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-08-30","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-10-23","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}